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he results from both epidemiologi-
cal and physiological studies have
demonstrated a strong association
between excess abdominal adipose tissue
and the presence of metabolic risk factors
forcoronaryheartdisease(CHD),includ-
ing insulin resistance, impaired glucose
tolerance, type 2 diabetes, dyslipidemia,
and increased circulating inﬂammatory
proteins (1–3). Abdominal adipose tissue
is a complex organ and is composed of
multiple distinct compartments and sub-
compartments, including subcutaneous
fat and intra-abdominal fat, which can be
further subdivided into retroperitoneal
and intraperitoneal fat, which can be di-
vided again into mesenteric and omental
fat masses. Intraperitoneal fat, which is also
knownasvisceraladiposetissue(VAT),is
considered a particularly important marker
of metabolic risk (4–6).
It has been hypothesized that in-
creased VAT is directly involved in the
pathogenesis of metabolic dysfunction
because VAT releases free fatty acids
(FFAs) and inﬂammatory proteins into
the portal vein, which are delivered to the
liver (7). However, most FFAs in the por-
tal circulation are derived from subcuta-
neous adipose tissue, and 20% of total
FFAs delivered to the liver or skeletal
muscle originate from lipolysis of VAT in
obesepeople(8,9).Moreover,mostinﬂam-
matory adipokines in the portal vein are
likelyderivedfromsubcutaneousfat,which
releases adipokines into the systemic circu-
lation that enter the portal vein through the
splanchnic bed (10). In addition, increased
VAT itself is not associated with insulin re-
sistanceordyslipidemiawithoutaconcom-
itant increase in intrahepatic triglycerides
(11). Therefore, these data do not support
an obvious causal link between intraperito-
neal fat and metabolic disease.
Surgical removal of the greater omen-
tum makes it possible to evaluate the im-
portance of VAT in the pathophysiology
of obesity in people. In fact, the results
from two randomized controlled studies
(12,13) have already been reported that
evaluated the effect of surgical removal of
the greater omentum on insulin action in
obesepatientsundergoingbariatricsurgery.
Unfortunately, the data and conclusions
from these studies are contradictory. In
one study (12), subjects randomized to
adjustable gastric banding plus omentec-
tomy had a greater improvement in oral
glucose tolerance and insulin sensitivity,
assessed by using an intravenous insulin
tolerance test, than subjects randomized
to adjustable gastric banding alone. How-
ever, the omentectomy group also expe-
rienced more weight loss than the
banding-alone group, which could have
contributedtotheobserveddifferencesin
insulin action. In the second study (13),
the prevalence of hyperglycemia and hy-
perinsulinemia 2 years after surgery were
not different in subjects randomized to
roux-en Y gastric bypass (RYGB) surgery
plusomentectomyorRYGBalone,butin-
sulin sensitivity was not directly assessed.
In this issue of Diabetes Care, Herrera
et al. (14) report the results of a 1-year
randomized controlled trial that evalu-
ated whether omentectomy provided ad-
ditional therapeutic effects on selected
metabolic variables and circulating in-
ﬂammatory proteins and adipokines in
obese patients who undergo RYGB sur-
gery (15). Twenty-two subjects were ran-
domized to have RYGB surgery or RYGB
surgery plus omentectomy. The rate of
weight loss was the same in both groups
throughout the study and reached a max-
imum of 30% weight loss at 1 year. The
amount of VAT removed (0.8 kg),
whichpresumablyrepresentsatleast25%
of total VAT, is greater than diet-induced
reductions in VAT that is associated with
a 25–50% increase in skeletal muscle and
liver insulin sensitivity (15–17). In their
subjects, surgery-induced weight loss re-
sulted in considerable improvement in
most metabolic and inﬂammatory out-
comes (plasma glucose, insulin, adiponec-
tin, and C-reactive protein concentrations;
lipidproﬁle;bloodpressure;impairedglu-
cose tolerance; and diabetes) but had
mixed results in plasma concentrations of
several other adipokines. However, there
was no signiﬁcant difference in any out-
come measure between groups. In addi-
tion, performing an omentectomy was
not trivial and had adverse effects; omen-
tectomyincreasedthedurationofsurgery
by 1 h and caused a serious complica-
tion in one subject.
The results from the study by Herrera
et al. have important implications regard-
ing the role of VAT in the pathophysiol-
ogy of obesity and suggest that increased
VAT does not directly cause metabolic
dysfunction. However, limitations in
study design leave two important ques-
tions unanswered. First, is it possible that
the overwhelming effect of weight loss in-
duced by RYGB surgery masked the po-
tential therapeutic effects of removing
VAT? Second, were the outcome measures
sensitive enough to detect metabolic im-
provements,particularlyininsulinsensitiv-
ity, which is probably the most common
metabolic abnormality associated with in-
creased VAT? Additional studies are still
needed that use more sensitive methods to
assess insulin action and that evaluate the
effect of omentectomy alone without con-
comitant weight loss surgery.
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